关抗流感药物zanamivir（Relenza）的国际 应用 专利将集中于今年下半年到期（ 消息来源 ），国内 外医药 企业 在仿药方面 将又 多出一种产品选择。 International patents on anti-influenza drug zanamivir (Relenza) will focus on expiring in the second half of this year ( source ), and domestic and foreign pharmaceutical companies will have another product choice in generic medicines .
In addition, GSK is in clinical trials of zanamivir intravenously, and the results will be announced next year. If this medication is successfully marketed, flu patients will have one more treatment option, and the demand for zanamivir will also explode. ） ( With GSK official news link )
是 生产zanamivir的主要原料 ， 我公司 将扩大产能以满足 可能增长的市场需求，并与合作伙伴共同开发zanamivir API 。 Sialic acid is the main raw material for the production of zanamivir . Our company will expand the production capacity to meet the market demand that may grow, and jointly develop zanamivir API with partners .